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Abstract 
 
Background/Aims:  
Orthostatic hypotension (OH) and QTc prolongation have potentially important prognostic 
and therapeutic consequences but have rarely been studied in patients with mild dementia. 
Methods: 
Patients with mild dementia were diagnosed according to consensus criteria after 
comprehensive standardised assessment. OH and QTc were assessed using standardised 
criteria.  
Results: 
OH was significantly more common in the dementia than in the control group, and systolic 
drop was higher in those with Dementia with Lewy bodies. There were no significant 
differences in QTc values between dementia and control subjects. 
Conclusion: 
OH occurs even in patients with mild dementia, in particular in DLB. QTc was not prolonged 
in patients with mild dementia compared with normal controls. 
 
 
 
 
 
  
Introduction 
 
 
A number of studies have highlighted the additional problem of autonomic dysfunction in 
patients with dementia. Dementia with Lewy bodies (DLB) and Parkinson’s Disease 
Dementia (PDD) account for 15-20% of late onset dementia [1,2], and are distressing 
conditions characterised by parkinsonism, visual hallucinations, fluctuating cognition, REM 
sleep behavioral disorder and marked sensitivity to neuroleptic drugs, resulting in major 
difficulties for clinical management [3]. There are some indications that autonomic 
dysfunction, which seems to be particularly prevalent in DLB [4,5], is associated with falls 
and syncope [6]. Falls are an important cause of morbidity, institutionalisation and mortality 
among persons with dementia [7,8], and are particularly common in DLB sufferers [9] . The 
association between autonomic dysfunction and falls may be mediated partly through 
orthostatic hypotension (OH)  [10], which appears to be a more common problem in DLB 
than in other dementias [4,11]. However, previous studies of orthostatic hypotension in 
dementia have been conducted in patients with moderately severe dementia, and thus little is 
known regarding the occurrence of OH in early dementia. 
 
Prolongation of the QT interval is another potential indicator of autonomic dysfunction [12-
14]. The significance of this phenomenon lies in its potential for fatal ventricular arrhythmia 
known as torsade de pointes. Prolonged QT interval is associated with an increased risk of 
cardiovascular morbidity and death in the general population [15-18].  
Certain drugs have been associated with QT prolongation, notably tricyclic antidepressants 
[19] and  some antipsychotics [20-22] .  There have also been case reports of QT interval 
prolongation possibly related to the use of an acetyl-cholinesterase-inhibitor [23-25]. QTc 
(frequency corrected QT interval) has been found to be significantly prolonged in patients 
with Parkinson’s disease [26,27] and was significantly correlated with disease stage according 
to Hoehn-Yahr stage [28] as well as with orthostatic hypotension [29]. DLB has clinical and 
biological similarities with dementia associated with Parkinson’s disease (PDD) and  these 
conditions are commonly grouped as Lewy body  dementia (LBD) [30], suggesting  that these 
findings also might apply to patients with DLB. To our knowledge, no studies have so far 
investigated the prevalence or the prognostic implications of QT prolongation in patients with 
dementia. Such information is of key importance, since QT prolongation might affect 
mortality and have important implications for drug therapy. 
 
With this background, we explored the frequency and clinical correlates of orthostatic 
hypotension and prolongation of the QT interval in patients with various forms of mild 
dementia. We hypothesized that orthostatic hypotension and prolongation of QTc are more 
common in early dementia than in normal elderly controls, and are more common in patients 
with LBD compared to controls and other dementia groups. Finally, we hypothesized that OH 
and prolongation of QTc are positively correlated. 
 
 
Materials and methods  
 
Patients with dementia 
Patients were recruited from the DemVest study, a prospective cohort study of 196 subjects 
with mild dementia in the counties of Rogaland and Hordaland in Western Norway [1] . 
During the inclusion period from March 2005 to March 2007, all referrals to outpatient clinics 
in geriatric medicine, old age psychiatry and neurology were screened for patients with a first 
  
time diagnosis of mild dementia. In order to select patients with mild dementia only, a Mini-
Mental State Examination (MMSE) score of at least 20 was required for inclusion. All 
participating subjects provided written informed consent, and the study was approved by the 
Regional Committee for Medical Research Ethics in Western Norway. The diagnoses of 
dementia subtypes were made according to consensus criteria [3,31-33], based on 
standardised instruments including the Informant Questionnaire on Cognitive Decline in the 
Elderly (the IQCODE), a questionnaire shown to be a reliable and valid instrument to detect 
dementia,[34], and the Hachinski ischemia scale [35], in addition to a battery of 
neuropsychiatric tests (see ref [1]for more details). Patients without dementia or with acute 
delirium, terminal illness, previous bipolar disorder or psychotic disorder, or having been 
recently diagnosed with life-threatening or severe somatic illness were excluded.  
[1]. 
 
Controls 
Spouses or friends of patients with PD participating in the ParkWest study [36] who were at 
least 70 years of age (NC-OH, n=81) provided control data  with regard to orthostatic 
hypotension. ECG was not available in this group. Therefore, for control data of QTc values, 
we recruited a convenience sample of non-demented elderly patients from non-cardiological 
medical wards and orthopaedic wards (mainly electively admitted) at Stavanger University 
Hospital (NC-ECG, n=23). Exclusion criteria were age below 65 years, treatment with QT 
prolonging drugs (amiodarone, sotalol, phenothiazines (chlorpromazine, levomepromazine, 
perphenazine, flupentixol, prometazine, alimetazine), tricyclic antidepressants (TCA)), 
chronic atrial fibrillation (AF),  or showing signs of  dementia according to the nurses in 
charge of the respective wards or according to medical records.  
 
Clinical assessments 
The patients were examined by a board-certified specialist in psychiatry, neurology or 
geriatric medicine and a research nurse. Prior to the study, both study clinicians and study 
nurses had participated in several training sessions on the use of diagnostic and clinical rating 
scales. The patients underwent a comprehensive assessment, including a detailed history using 
a semi structured interview with regard to demographics, previous diseases and drug history, 
neuropsychiatric assessment and clinical examination. Blood tests, electrocardiogram (ECG) 
and MRI of the brain were performed.  The assessments took place during normal office 
hours (8 a.m. to 4 p.m). 
 
Blood pressure measurements 
Blood pressure was measured using an analogue sphygmomanometer, once with the subject in 
the supine or in some cases the sitting position, and then once within 3 minutes after standing 
up. 
Orthostatic hypotension (OH) was defined as a reduction of systolic blood pressure by at least 
20 mm Hg or by a drop in diastolic blood pressure of at least 10 mm Hg within 3 minutes of 
standing [10].  
 
Electrocardiographic measurements 
The patients had a resting 12-lead surface ECG taken, at a paper speed of 50 mm/s, using the 
ECG recorder available in the respective outpatient clinic. Each ECG transcript was prior to 
measurements enlarged to 200% of its original size, using a Xerox/copying machine. Patients 
with missing or unreadable ECGs, ECGs showing rhythms other than sinus rhythm, or with 
RBBB or LBBB were excluded from QTc measurements. ECGs showing left anterior 
hemiblock or incomplete right bundle branch block were included. Reasons for not measuring 
  
the QT interval were atrial fibrillation (n=5), RBBB (n=1), LBBB (n=1), pacemaker rhythm 
(n=1), poor quality/technical reasons (n=6).  
 
 
The QT and RR intervals were obtained manually, each least square on the ECG transcript 
representing 0,02 seconds at a paper speed of 50 mm/s.. The intervals were measured with a 
resolution of up to 1/5 of the least squares, i.e. 0,004 seconds.  QT was measured in Lead II 
[37] The end of the T-wave was defined as the point of return to the iso-electric line in Lead 
II. The beginning of the QRS-complex was identified in Lead II or in some cases from a 
corresponding lead where it was more clearly defined. The QT interval measurement was 
based on one QT interval, but was averaged from 2 or 3 intervals in patients with sinus 
arrhythmia. The ECGs were first examined by an experienced specialist in geriatrics and 
internal medicine (HS), and then by an experienced academic cardiologist (DWN), who was 
blinded to the measurements made by the geriatrician. In cases of divergent values, we re-
examined the ECGs together, with previous measurements out of sight,  and a consensus was 
reached in each case.  In one instance the interval was measured in other leads than Lead II, 
due to a poorly defined T. 
The QT interval was adjusted for heart rate according to Bazett’s formula [38], thereby 
obtaining the QTc. In the elderly, QTc above 420 ms is associated with an increased risk for 
all-cause mortality [17]. From a more clinical perspective, the international regulatory 
guidance for drug development suggests a sex-independent threshold for QTc interval 
prolongation of  450 ms [39]. A QTc longer than 500 ms is an accepted threshold for 
significant arrhythmia risk  [40]. 
 
Statistics 
Kruskal-Wallis test was used to assess statistical differences, followed by post-hoc Mann-
Whitney U Test if significant. For categorical variables, we used Chi-Square test followed by 
pair-wise comparison if significant. For bivariate correlation, Pearson correlation coefficient 
or Spearman Rank Order Correlation were used.  
 
For calculation of the confidence interval of a proportion and for calculation of the 
significance of the difference between two independent proportions, we used calculators 
available at http://faculty.vassar.edu/lowry/VassarStats.html. All the other statistical tests 
were performed using SPSS version 16.0 for Windows.  
 
Significance was taken as p<0.05. 
 
 
Results  
 
A total of 262 participants were included in this study: 158 patients with early dementia and a 
total of 104 control subjects (NC-OH, n=81 and NC-QT, n=23). Patients and control subjects 
(excluding NC-ECG, for which we had limited medical information) were well matched with 
regard to age, heart disease and diabetes mellitus. Patients were divided into AD, DLB, PDD, 
and a mixed group consisting of patients with vascular dementia (VaD), frontotemporal 
dementia (FTD) or alcoholic dementia (Table 1). There were more females in the AD group 
than in the other dementia groups. In the mixed group, which included a majority of VaD 
patients, prior stroke was more frequent than in the DLB patients. There were no significant 
between-group differences in the number of drugs taken regularly or the proportion of patients 
taking QT interval prolonging drugs (amiodarone, sotalol, phenothiazines and tricyclic 
  
antidepressants). As expected, all PDD patients were taking L-DOPA, and more AD than NC 
subjects were taking OH-related drugs (Table 1). 
 
 
Orthostatic hypotension (OH) 
The OH results are shown in table 2.  41% of the dementia patients had OH, compared to only 
14% of the controls (p=0,0002), and OH was more common in both DLB, PDD and AD 
patients compared to the normal controls. Significant between-group differences were also 
found for standing systolic and supine diastolic BP, and for systolic BP drop. DLB and PDD 
had significantly lower standing systolic blood pressures than AD and normal controls. PDD 
had significantly lower supine or seated diastolic BP than AD, and the AD group had 
significantly lower supine or seated diastolic BP than the mixed group. The systolic BP drop 
from the supine to the standing position was significantly larger in the DLB group and the 
mixed group than in normal controls (Table 2).  
 
Prolongation of QTc 
A total of 136 patients had a valid ECG, and 50% of the patients had QTc > 426 ms, and 25% 
> 442 ms (the values of 426 and 442 ms represent the 50 percentile and the 75 percentile, 
respectively). We did not find any significant differences in the prevalence of QTc 
prolongation between the groups. Similarly, mean QTc did not differ significantly between 
groups. These results did not change when patients on QT interval prolonging drugs (n=8) 
were excluded from the analyses (Table 3). The 2 patients with PDD with valid ECGs had 
QTc values of 424 and 517 ms, respectively. Of 112 patients with potassium data, only 3 
(2.7%) had hypokalemia and none of 34 with magnesium values had hypomagnesemia 
(defined as values below the cut-offs for the local laboratory). 
 
OH vs. QTc prolongation 
There were no statistically significant correlations between QTc values and systolic BP drop 
(p=0,976) or diastolic BP drop (p=0,249), and there was no association between OH and 
prolongation of QTc >420 ms  (p=0,939) or QTc > 450 ms  (p=0,508) (Spearman’s rho, not 
including subjects taking QTc prolonging drugs).  
 
 
Discussion  
 
This is the first study exploring QTc in patients with dementia. We found no evidence of 
prolongation of QTc in patients with mild dementia, including those with DLB. For PDD, our 
data show QTc prolongation, but the small number of PDD patients does not permit any firm 
conclusions to be drawn. In contrast, orthostatic hypotension was more common in patients 
with mild dementia than in normal control subjects, and standing systolic blood pressure was 
lower in patients with DLB than in AD and NC, extending previous findings in patients with 
moderately severe dementia [4,11]. The absence of a difference in QTc suggests that dementia 
patients do not intrinsically have higher risks of sudden death associated with prolongation of 
QTc, compared to non-demented elderly. This lack of a difference is particularly interesting in 
view of the fact that many of  the dementia patients were taking drugs associated with QTc 
prolongation in case reports, e.g. cholinesterase inhibitors.  
 
 
Pathophysiological mechanisms 
  
Our findings suggest that different mechanisms underlie OH and prolongation of QT time. 
OH may have several causes in an elderly patient, including medication, dehydration, age 
related changes and autonomic failure [41]. Both parasympathetic and sympathetic 
dysfunction may contribute to OH [41]. In a previous study, DLB showed impairment of both 
sympathetic and parasympathetic function, whereas AD only showed impairment in one 
sympathetic response (orthostasis) [4] . The QT interval, on the other hand, is affected by a 
complex interplay between the sympathetic and the parasympathetic systems [14,42]. In 
diabetic patients, QTc was found to be a specific, but insensitive marker of autonomic failure 
[13]. This might also be the case in patients with dementia.  In Parkinson’s disease (PD), the 
QTc was found to be significantly prolonged [42]. We found no prolongation of QTc in DLB 
patients. Therefore our findings point to the possibility of different pathophysiological 
mechanisms being involved in these two diseases. Whereas PD involves brain stem nuclei 
early in course, DLB is considered to start in the neocortex and then gradually involve brain 
stem regions [43].  Our findings lend some support to this hypothesis, since one might 
imagine the QTc to be prolonged if the brain stem was affected in early DLB. Thus, it is 
possible that QTc prolongation occurs only in more advanced DLB, if at all. Alternatively, the 
absence of QTc prolongation in early DLB may be related to cardiac sympathetic denervation 
[44], which has been demonstrated even in early DLB by means of MIBG myocardial 
scintigraphy [45]. However, cardiac sympathetic degeneration has been found also in PD 
[46,47], which makes this explanation less likely .  
 
Methodological discussion: 
There are some methodological limitations which need to be addressed when interpreting our 
findings. Firstly, the method of diagnosing OH was not fully standardized. Some of the 
dementia patients had their blood pressure measured in the sitting, instead of the supine 
position. Moreover, at least 20-30 percent of dementia patients have a delayed orthostatic 
response [48], which would have been missed with our methodology. These limitations may 
have led to an underestimation of the prevalence of OH in the dementia groups.  On the other 
hand, we did not adjust for the effects of medications potentially affecting OH, which could 
have led to an overestimation of the prevalence of OH in the dementia groups as compared to 
the NC group. 
In addition, ECG was available in relatively few patients, limiting the statistical power to 
detect significant differences. However, there was not even a trend toward more QTc 
prolongation in DLB compared to normal control subjects. Moreover, the measurement of RR 
and QT intervals was based on only one interval for each person, which might negatively 
affect the reliability of the measurements [37,49].  
Furthermore, we did not have a full and systematic dataset regarding electrolyte levels at the 
time of the ECG recordings, and, therefore, could not fully evaluate the possible effects of 
hypokalemia or hypomagnesemia on the QT interval. However, of those with electrolyte data,  
less than 3% had hypokalemia and none had hypomagnesemia, suggesting that hypokalemia 
and hypomagnesemia did not significantly influence the findings. 
 
 
Clinical implications: 
We found that OH is increased even early in the dementia process. OH is associated with 
increased risk of falls [50], impaired attention [51], and higher mortality [52], and should be 
adequately assessed already at the time of diagnosis of dementia, in particular in patients with 
DLB. Although QTc was not prolonged in patients with mild dementia compared with normal 
controls, 50% of patients with dementia had a QTc above 426 ms, which is an independent 
predictor of mortality in older men and women, with higher values being associated with 
  
higher risk [17].  Future studies are needed to study whether DLB and PDD patients are 
particularly sensitive to drugs inducing prolongation of QTc, and whether prolonged QTc and 
OH may have prognostic implications in terms of falls or mortality. 
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 Table 1. Clinical characteristics  
 
 
 
Numbers represent mean (SD) or number of subjects (%). 
Statistical analyses performed using Kruskall-Wallis or chi square test and post-hoc Mann-
Whitney and pairwise chi square if significant. 
 
Post-hoc pairwise comparisons with p < 0.05: 
1) PDD vs AD; 2) DLB vs. VaD/FTD/ALC, 3) PDD vs. VaD/FTD/Alc; 4) AD vs. 
VaD/FTD/Alc; 5) VaD/Alc/FTD vs. NC-OH; 6) PDD vs. NC-OH; 7) AD vs. NC-OH 
 
 
 
 
* antianginals, antihypertensives, tricyclic antidepressants (TCA), non-TCA antidepressants, 
MAO-inhibitors, dopamine agonists, sedatives, dipyridamol, phenothiazines 
 
** amiodarone (n=0), sotalol, phenothiazines, TCA 
 
 DLB PDD AD Vad/FTD/Alc NC-
OH 
NC-
QT 
p 
n= 39 11 128 18 81 23  
Age, yrs 78,1 
(8,2) 
73,4 
(8,8) 
75,6(7,7) 74,7 (7,6) 75,5 
(3,9) 
77,8 
(7,5) 
 0,170 
 
Women  
 
20 
(51%) 
2 
(18%) 
89 
(70%) 
5 (28%) 36 
(44%) 
16 
(70%) 
0,000
1
 
 
MMSE score 23,7 
(2,6) 
25,7 
(2,0) 
23,8 
(2,2) 
23,5 (2,8) - - 0,053 
 
 
Hypertension 
 
13 
(34%) 
1 (9%) 57 
(45%) 
10 (56%) 37 
(46%) 
- 0.039
3,6
 
 
Heart disease 
 
7 
(18%) 
1 (9%) 23 
(18%) 
4 (22%) 17 
(21%) 
- 0,229 
 
Previous 
stroke 
5 
(13%) 
0 (0%) 17 
(13%) 
7 (39%) 3 
(4%) 
- 0,000
2,3,4,5
 
 
Diabetes 
mellitus 
4 
(11%) 
0 (0%) 12 (9%) 1 (4%) 7 
(9%) 
- 0,586 
 
No. of drugs 
 
4,3 
(2,4) 
4,4 
(1,6) 
3,9 (2,6) 4,4 (2,7) - - 0,422  
Patients 
using OH 
related 
drugs* 
27 
(69%) 
10/10 
(100%) 
88 
(69%) 
15 (83%) 43 
(53%) 
 
*** 
- 0,005
5.6.7
 
 
Patients 
using QT 
interval 
prolonging 
drugs** 
1 
(3%) 
0 (0%) 7 (6%) 0 (0%) - 0 
(0%) 
0,808  
  
*** antidepressants, antihypertensives, antipsychotics, PD-drugs, sedatives, data on other OH 
related drugs not available 
 
 
Table 2. Orthostatic hypotension (OH) 
 
 DLB PDD AD VaD/FTD/alc NC-OH p 
OH 
present 
(%,95% CI 
With 
continuity 
correction, 
without -) 
11/26 
(42%, 
26-61,24-
63) 
6/11 
(55%, 
28-79, 
25-82) 
43/105  
(41%, 32-
51, 32-51) 
 
5/16  
(31%, 14-56, 12-
59) 
11/79 (14%, 
8-23, 7-24) 
0,000
5,6,7
  
 
 
n=237 
Systolic 
BP, supine 
or seated 
(mm Hg), 
median, 
min-max  
150, 110-
210 
 
135, 110-
200 
150, 110-
200 
 
150, 90-240 
 
140, 91-210  0,128 
 
 
 
 
n=269 
Systolic 
BP, 
standing 
(mm Hg), 
median, 
min-max  
128,5, 90-
200 
 
126, 90-
190 
150, 100-
200 
 
140, 110-230 
 
140, 90-190 0,015 
1,2,5.6
  
 
 
n=239 
Diastolic 
BP, supine 
or seated 
(mm Hg), 
median, 
min-max 
80, 30-110 
 
80, 70-90 85, 60-
115 
 
80, 60-150 
 
85, 59-120 0,030
1,3
  
 
 
n=269 
Diastolic 
BP, 
standing 
(mm Hg), 
median, 
min-max  
80, 50-120 
 
80, 60-
110 
90, 60-
120 
 
82,5, 70-150 
 
85, 60-120 0,072 
 
 
 
 
n=239 
Systolic 
BP drop  
(mmHg)  
median, 
min-max 
13, -11-53 15, -10-
30 
5, -50-40 10, -20-40 0,-26-30 p=0,020
4,6
 
 
 
n=237 
Diastolic 
BP drop 
(mm Hg) 
median, 
min-max 
0, -20-20 0, -20-11 0, -20-25 0, -15-10 0, -11-30 0,428 
 
 
 
n=237 
 
Post-hoc pairwise comparisons with p < 0.05: 
1) PDD vs AD; 2) DLB vs. AD; 3) AD vs. VaD/FTD/Alc; 4) VaD/Alc/FTD vs. NC-OH; 5) PDD vs. NC-
OH; 6) DLB vs. NC-OH; 7) AD vs. NC-OH 
 
 
 
 
 
  
Table 3. QTc prolongation  
 
 
 DLB (n=22) AD (n=81) NC-QT 
(n=23) 
p 
QTc , mean (SD)
 1
 
 
 
429,5 (39,5) 
 
424,2 (28,2) 
 
438,9 (30,7) 
 
0,125
3
 
 
QTc, mean (SD)
 2
 
 
 
429,5 (39,5) 
 
 
423,9 (28,1) 
 
 
438,9 (30,7) 
 
 
0,117
3
 
QTc >420 ms
2
 
n  (%, 95% CI, with 
and without 
continuity 
correction) 
12 (55, 35-73, 
33-75)  
43 (56, 45-66, 
44-67) 
15 (65, 45-81, 
43-83) 
0,765
4
 
 
QTc >450 ms
2
 
n (% with 95% CI, 
with and without 
continuity 
correction) 
4 (18, 7-39, 6-
41) 
15 (20, 12-30, 
12-30) 
9 (39, 22-59, 
20-61) 
0,211
4
 
 
1) Patients on QT prolonging drugs included  
 
2) Patients on QT prolonging drugs excluded  
 
3) Kruskal-Wallis test 
 
4) Chi-square, Fisher’s exact probability test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
